Paulo Alegria

Paulo Alegria

Auto-generated profile, based on publicly available information

Paulo Alegria

17 Serviço de Neurologia, Hospital Beatriz Ângelo, 2674-514 Loures, Portugal

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2007 in Brain
Verified
Journal Article
Open access
PDF file
GSGiovanni Stevanin
Giovanni Stevanin
HAHamid Azzedine
Hamid Azzedine
PDPaola Denora
Paola Denora
ABAmir Boukhris
Amir Boukhris
MTMeriem Tazir
Meriem Tazir
SCSPATAX consortium
SPATAX consortium
Hereditary spastic paraplegias (HSP) are neurodegenerative diseases mainly characterized by lower limb spasticity associated, in complicated forms, with additional neurological signs. We have analysed a large series of index patients (n = 76) with this condition, either from families with an autosomal recessive inheritance (n = 43) or isolated patients (n = 33), for mutations in the recently identified SPG11 gene. We found 22 truncating mutations, including the first four splice-site mutations, segregating in seven isolated cases and 13 families. Nineteen mutations were novel. Two recurrent mutations were found in Portuguese and North-African patients indicating founder effects in these populations. The mutation frequency varied according to the phenotype, from 41%, in HSP patients presenting with a thin corpus callosum (TCC) visualized by MRI, to 4.5%, in patients with mental impairment without a TCC. Disease onset occurred during the first to the third decade mainly by problems with gait and/or mental retardation. After a mean disease duration of 14.9 ± 6.6 years, the phenotype of 38 SPG11 patients was severe with 53% of patients wheelchair bound or bedridden. In addition to mental retardation, 80% of the patients showed cognitive decline with executive dysfunction. Interestingly, the phenotype also frequently included lower motor neuron degeneration (81%) with wasting (53%). Slight ocular cerebellar signs were also noted in patients with long disease durations. In addition to a TCC (95%), brain MRI revealed white matter alterations (69%) and cortical atrophy (81%), which worsened with disease duration. In conclusion, our study reveals the high frequency of SPG11 mutations in patients with HSP, a TCC and cognitive impairment, including in isolated patients, and extends the associated phenotype.

2 July 2014 in Brain
Verified
Journal Article
Open access
PDF file
NMNiccolò E. Mencacci
Niccolò E. Mencacci
Ioannis Ugo IsaiasIoannis Ugo Isaias
Ioannis Ugo Isaias
MRMartin M. Reich
Martin M. Reich
CGChristos Ganos
Christos Ganos
VPVincent Plagnol
Vincent Plagnol
NWNicholas W. Wood
Nicholas W. Wood
GTP cyclohydrolase 1, encoded by the GCH1 gene, is an essential enzyme for dopamine production in nigrostriatal cells. Loss-of-function mutations in GCH1 result in severe reduction of dopamine synthesis in nigrostriatal cells and are the most common cause of DOPA-responsive dystonia, a rare disease that classically presents in childhood with generalized dystonia and a dramatic long-lasting response to levodopa. We describe clinical, genetic and nigrostriatal dopaminergic imaging ([123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane single photon computed tomography) findings of four unrelated pedigrees with DOPA-responsive dystonia in which pathogenic GCH1 variants were identified in family members with adult-onset parkinsonism. Dopamine transporter imaging was abnormal in all parkinsonian patients, indicating Parkinson’s disease-like nigrostriatal dopaminergic denervation. We subsequently explored the possibility that pathogenic GCH1 variants could contribute to the risk of developing Parkinson’s disease, even in the absence of a family history for DOPA-responsive dystonia. The frequency of GCH1 variants was evaluated in whole-exome sequencing data of 1318 cases with Parkinson’s disease and 5935 control subjects. Combining cases and controls, we identified a total of 11 different heterozygous GCH1 variants, all at low frequency. This list includes four pathogenic variants previously associated with DOPA-responsive dystonia (Q110X, V204I, K224R and M230I) and seven of undetermined clinical relevance (Q110E, T112A, A120S, D134G, I154V, R198Q and G217V). The frequency of GCH1 variants was significantly higher (Fisher’s exact test P-value 0.0001) in cases (10/1318 = 0.75%) than in controls (6/5935 = 0.1%; odds ratio 7.5; 95% confidence interval 2.4–25.3). Our results show that rare GCH1 variants are associated with an increased risk for Parkinson’s disease. These findings expand the clinical and biological relevance of GTP cycloydrolase 1 deficiency, suggesting that it not only leads to biochemical striatal dopamine depletion and DOPA-responsive dystonia, but also predisposes to nigrostriatal cell loss. Further insight into GCH1-associated pathogenetic mechanisms will shed light on the role of dopamine metabolism in nigral degeneration and Parkinson’s disease.

1 January 2012 in Frontiers in Neurology
Verified
Journal Article
Open access
LALuísa Alves
Luísa Alves
ACAna Sofia A. Correia
Ana Sofia A. Correia
RMRita Miguel
Rita Miguel
PAPaulo Alegria
Paulo Alegria
PBPaulo Bugalho
Paulo Bugalho
Investigation in the field of Alzheimer’s disease (AD), the commonest cause of dementia, has been very active in recent years and it may be difficult for the clinician to keep up with all the innovations and to be aware of the implications they have in clinical practice. The authors, thus, reviewed recent literature on the theme in order to provide the clinician with an updated overview, intended to support decision-making on aspects of diagnosis and management. This article begins to focus on the concept of AD and on its pathogenesis. Afterward, epidemiology and non-genetic risk factors are approached. Genetics, including genetic risk factors and guidelines for genetic testing, are mentioned next. Recommendations for diagnosis of AD, including recently proposed criteria, are then reviewed. Data on the variants of AD is presented. First approach to the patient is dealt with next, followed by neuropsychological evaluation. Biomarkers, namely magnetic resonance imaging, single photon emission tomography, FDG PET, PiB PET, CSF tau, and Aβ analysis, as well as available data on their diagnostic accuracy, are also discussed. Factors predicting rate of disease progression are briefly mentioned. Finally, non-pharmacological and pharmacological treatments, including established and emerging drugs, are addressed.

30 August 2005 in Human Mutation
Verified
Journal Article
Open access
PDF file
LVL. Vilarinho
L. Vilarinho
MCM.L. Cardoso
M.L. Cardoso
PGPaulo Miranda Gaspar
Paulo Miranda Gaspar
CBC. Barbot
C. Barbot
LALuisa Azevedo
Luisa Azevedo
CJC. Jakobs
C. Jakobs
We studied 21 patients, from 18 families, with L‐2‐hydroxyglutaric aciduria (L‐2‐HGA), a rare neurometabolic disorder with a homogeneous presentation: progressive neurodegeneration with extrapyramidal and cerebellar signs, seizures, and subcortical leukoencephalopathy. Increased levels of L‐2‐hydroxyglutaric acid in body fluids proved the diagnosis of L‐2‐HGA in all 21 patients. We analyzed the L‐2‐HGA gene (L2HGDH), recently found to be mutated in consanguineous families with L‐2‐HGA, and identified seven novel mutations in 15 families. Three mutations appeared to be particularly prevalent in this Portuguese panel: a frameshift mutation (c.529delC) was detected in 12 out of 30 mutant alleles (40%), a nonsense mutation (c.208C>T; p.Arg70X) in 7/30 alleles (23%), and a missense mutation (c.293A>G; p.His98Arg) in four out of 30 mutant alleles (13%), suggesting that common origin may exist. Furthermore, two novel missense (c.169G>A; p.Gly57Arg, c.1301A>C; p.His434Pro) and two splice error (c.257‐2A>G, c.907‐2A>G) mutations were found. All the mutations presumably lead to loss‐of‐function with no relationship between clinical signs, progression of the disease, levels of L‐2‐HGA and site of the mutation. In the three remaining families, no pathogenic mutations in the L‐2‐HGA were found, which suggests either alterations in regulatory regions of the gene or of its intervening sequences, compound heterozygosity for large genomic deletion and, or further genetic heterogeneity.

2 July 2002 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
PAPaulo Alegria
Paulo Alegria
LLLuís Lebre
Luís Lebre
CCCristina Chagas
Cristina Chagas